Jade Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
JBIO Nasdaq 2836 jadebiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Jade Biosciences, Inc.

Institutional investors in Jade Biosciences, Inc. (NASDAQ:JBIO) must be dismayed after prices dropped by 16% last week - Jan 6th, 2026 5:07 am
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference - Jan 5th, 2026 5:00 am
Jade Biosciences Announces $45 Million Private Placement - Dec 15th, 2025 5:00 am
Jade Biosciences (JBIO): Analyst Lauds Entry into Market - Dec 10th, 2025 12:15 pm
Does Jade Biosciences, Inc. (JBIO) Have the Potential to Rally 65% as Wall Street Analysts Expect? - Dec 4th, 2025 7:55 am
What Makes Jade Biosciences, Inc. (JBIO) a New Buy Stock - Nov 18th, 2025 10:00 am
Wall Street Analysts Predict a 52.5% Upside in Jade Biosciences, Inc. (JBIO): Here's What You Should Know - Nov 18th, 2025 7:55 am
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 13th, 2025 2:05 pm
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 - Nov 8th, 2025 9:00 am
Jade Biosciences to Participate in Upcoming Conferences - Nov 3rd, 2025 5:00 am
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025 - Oct 17th, 2025 2:05 pm
Jade Biosciences Raises $135 Million Through Private Placement - Oct 7th, 2025 6:11 am
Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases - Oct 7th, 2025 5:05 am
Jade Biosciences Announces $135 Million Private Placement - Oct 7th, 2025 5:00 am
Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy - Sep 2nd, 2025 5:00 am
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 13th, 2025 2:05 pm
The early winner in the 'Dexit' war for corporate relocations: Nevada - Jul 10th, 2025 2:00 am
Jade Biosciences to Participate in Two Upcoming Investor Conferences - Jul 8th, 2025 5:00 am
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer - Jul 1st, 2025 5:00 am
2 Small-Cap Stocks Under $10 to Buy With Big Potential - Jun 24th, 2025 5:30 am